Liposome-entrapped topoisomerase inhibitors
0 Assignments
0 Petitions
Accused Products
Abstract
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 μmole drug per μmole lipid.
13 Citations
57 Claims
-
1-26. -26. (canceled)
-
27. A composition for administration of 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, comprising
liposomes composed of at least about 20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer chain, said liposomes having an inside/outside ion gradient effective to retain the 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin within the liposomes; - and
entrapped in the liposomes, the 7-(2-(N-isopropylamino)ethyl)-(20S-camptothecin at a concentration of at least about 0.20 μ
mole drug per mole lipid,wherein said liposome composition provides at least a four-fold increase in anti-tumor activity over the anti-tumor activity of the drug in free-form. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35)
- and
-
36. A composition for administration of 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, comprising
liposomes composed of vesicle-forming lipids derivatized with a hydrophilic polymer chain and having an inside/outside ion gradient effective to retain the 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin within the liposomes; - and
entrapped in the liposomes, the 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin at a concentration of at least about 0.20 μ
mole drug per μ
mole lipid,wherein said liposome composition provides at least a four-fold increase in anti-tumor activity over the anti-tumor activity of the drug in free-form. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44, 45)
- and
-
46. A composition for treating a tumor in a subject, comprising liposomes composed of a vesicle-forming lipid and between about 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer, said liposomes being formed under conditions that distribute the polymer on both sides of the liposomes'"'"' bilayer membranes;
- and
entrapped in the liposomes, a topoisomerase inhibitor at a concentration of at least about 0.10 μ
mole topoisomerase inhibitor per μ
mole lipid,wherein said liposomes have an inside/outside ion gradient sufficient to retain the topoisomerase inhibitor within the liposomes at the specified concentration prior to in vivo administration, and wherein said liposome-entrapped topoisomerase inhibitor has a longer blood circulation lifetime than the topoisomerase inhibitor in free form, and wherein the topoisomerase inhibitor is an ionizable camptothecin derivative. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53)
- and
-
54. A composition for administration of a topoisomerase inhibitor, comprising liposomes composed of vesicle-forming lipids and having an inside/outside ion gradient effective to retain the drug within the liposomes;
- and
entrapped in the liposomes, a topoisomerase inhibitor which is an ionizable camptothecin derivative at a concentration of at least about 0.20 μ
mole topoisomerase inhibitor per μ
mole lipid. - View Dependent Claims (55, 56, 57)
- and
Specification